| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
5,780,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3302 - $0.3302 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Phio Pharmaceuticals is developing therapeutics that use its INTASYL™ technology to target both tumor and immune cells by regulating genes to strengthen a patient's immune system while weakening tumor defense mechanisms. Co.'s INTASYL-based therapeutics are used to: strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT), and directly modify cells in the tumor microenvironment to weaken a tumor's defense. Co.'s lead product candidate being developed by Co. in ACT is PH-762. Co.'s second product candidate in development for use in ACT is PH-894. Co.'s INTASYL compound PH-804 is also being developed for use in ACT.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
2,500 |
2,500 |
6,500 |
22,216 |
| Total Buy Value |
$2,275 |
$2,275 |
$14,195 |
$22,362 |
| Total People Bought |
1 |
1 |
2 |
2 |
| Total Buy Transactions |
1 |
1 |
4 |
12 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kontulis Caitlin |
Secretary & VP Finance & Admin |
• – – |
2024-03-01 |
4 |
D |
$0.96 |
$321 |
D/D |
(335) |
10,643 |
|
- |
|
| Bitterman Robert J |
President & CEO |
• • – |
2024-02-26 |
4 |
B |
$0.91 |
$2,275 |
D/D |
2,500 |
18,990 |
2.73 |
- |
|
| Bitterman Robert J |
President & CEO |
• • – |
2024-02-20 |
4 |
D |
$0.76 |
$1,371 |
D/D |
(1,804) |
16,490 |
|
- |
|
| Kontulis Caitlin |
Secretary & VP Finance & Admin |
• – – |
2024-02-17 |
4 |
D |
$0.66 |
$345 |
D/D |
(523) |
10,978 |
|
- |
|
| Kontulis Caitlin |
Secretary & VP Finance & Admin |
• – – |
2024-02-15 |
4 |
D |
$0.65 |
$428 |
D/D |
(658) |
11,501 |
|
- |
|
| Bitterman Robert J |
President & CEO |
• • – |
2023-10-01 |
4 |
D |
$1.51 |
$1,385 |
D/D |
(917) |
18,294 |
|
- |
|
| Bitterman Robert J |
President & CEO |
• • – |
2023-07-01 |
4 |
B |
$2.84 |
$2,840 |
D/D |
1,000 |
19,211 |
2.73 |
- |
|
| Bitterman Robert J |
President & CEO |
• • – |
2023-06-30 |
4 |
B |
$2.88 |
$2,880 |
D/D |
1,000 |
18,211 |
2.73 |
- |
|
| Ferrara Robert L |
Director |
– • – |
2023-06-14 |
4 |
B |
$3.10 |
$6,200 |
D/D |
2,000 |
6,000 |
2.39 |
- |
|
| Kontulis Caitlin |
Secretary & VP Finance & Admin |
• – – |
2023-03-01 |
4 |
D |
$5.49 |
$1,839 |
D/D |
(335) |
12,159 |
|
- |
|
| Bitterman Robert J |
President & CEO |
• • – |
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
17,211 |
|
- |
|
| Freeman Jonathan E |
Director |
– • – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
3,197 |
|
- |
|
| Bradford Patricia A |
Director |
– • – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
3,167 |
|
- |
|
| Cauwenbergh Geert |
Director |
– • – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
4,235 |
|
- |
|
| Kontulis Caitlin |
Secretary & VP Finance & Admin |
• – – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
12,494 |
|
- |
|
| Lockshin Curtis |
Director |
– • – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
3,197 |
|
- |
|
| Ferrara Robert L |
Director |
– • – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
4,000 |
|
- |
|
| Kontulis Caitlin |
Secretary & VP Finance & Admin |
• – – |
2023-02-15 |
4 |
D |
$5.20 |
$3,416 |
D/D |
(657) |
7,994 |
|
- |
|
| Bitterman Robert J |
Interim Executive Chairman |
• • – |
2022-12-14 |
4 |
B |
$0.39 |
$780 |
D/D |
2,000 |
74,541 |
2.73 |
- |
|
| Bitterman Robert J |
Interim Executive Chairman |
• • – |
2022-12-07 |
4 |
B |
$0.39 |
$780 |
D/D |
2,000 |
72,541 |
2.73 |
- |
|
| Bitterman Robert J |
Interim Executive Chairman |
• • – |
2022-12-05 |
4 |
B |
$0.43 |
$860 |
D/D |
2,000 |
70,541 |
2.73 |
- |
|
| Ferrara Robert L |
Director |
– • – |
2022-12-02 |
4 |
B |
$0.41 |
$2,041 |
D/D |
5,000 |
30,000 |
2.31 |
- |
|
| Bitterman Robert J |
Interim Executive Chairman |
• • – |
2022-11-29 |
4 |
B |
$0.40 |
$86 |
D/D |
215 |
68,541 |
2.73 |
- |
|
| Bitterman Robert J |
Interim Executive Chairman |
• • – |
2022-11-25 |
4 |
B |
$0.42 |
$1,050 |
D/D |
2,500 |
68,326 |
2.73 |
- |
|
| Ferrara Robert L |
Director |
– • – |
2022-11-23 |
4 |
B |
$0.41 |
$820 |
D/D |
2,000 |
25,000 |
2.31 |
- |
|
134 Records found
|
|
Page 1 of 6 |
|
|
